Global challenges in breast cancer detection and treatment
- PMID: 35219542
- PMCID: PMC9097801
- DOI: 10.1016/j.breast.2022.02.003
Global challenges in breast cancer detection and treatment
Abstract
Breast cancer represents an urgent global priority. While this is a universal issue, and as the burden of the disease is increasing globally, current estimates indicate that in the next couple of decades, much of the incidence and mortality related to breast cancer will be seen in underserved populations. The fragile and ill-prepared healthcare systems in low- and middle-income countries (LMIC) need to address this challenge and find solutions with their limited resources. Significant disparities can be identified in stage at presentation as the ability to detect the disease in earlier stages is compromised in these scenarios leading to worse outcomes associated to late diagnoses. Furthermore, access to healthcare in general and to basic surgical, radiotherapy and systemic care is suboptimal additionally limiting treatment results. With a small portion of their budget allocated to healthcare, LMIC need to make the most of their resources prioritizing cost-effective strategies that could offer the best possible results. Countries that invest in women's health do develop into healthier, more educated, and importantly, more productive societies with benefits seen across generations. Finally, recognition of inequities should stimulate a concerted effort engaging all involved stakeholders to find context-adapted solutions to improve healthcare outcomes.
Keywords: Breast cancer detection; Breast cancer treatment; Early diagnosis; Healthcare discrepancies; Low- and middle-income countries; Screening.
Copyright © 2022 The Author. Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Grants/research support: (to the institution) Pfizer, Novartis, Amgen, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Roche/Genentech, Lilly, Sanofi, Taiho Pharmaceutical, Mylan, Merrimack, Merck, AbbVie, Astellas Pharma, BioMarin, Bristol-Myers Squibb, Daiichi Sankyo, Abraxis Biosciences, AB Science, Asana Biosciences, Medivation, Exelixis, ImClone Systems, LEO Pharma, Millennium, Merck KGaA, Shanghai Henlius Biotech, Polyphor, PharmaMar. Ownership or Stocks: Biomarker, Tummi, MEDSir. Advisory Boards and Consulting: Boehringer-Ingelheim, GSK, Novartis, Pfizer, Roche/Genentech, Eisai, Bayer, MSD, Astra Zeneca, Zodiac, Lilly, Sanofi.
References
-
- Ferlay J., Ervik M., Lam F., et al. 2020. Global cancer observatory: cancer today.https://gco.iarc.fr/today accessed Dec 31, 2020.
-
- WHO report on cancer: setting priorities, investing wisely and providing care for all. World Health Organization; Geneva: 2020. Licence: CC BY-NC-SA 3.0 IGO.
-
- Wild C.P., Weiderpass E., Stewart B.W., editors. World cancer report: cancer research for cancer prevention. International Agency for Research on Cancer; Lyon, France: 2020. http://publications.iarc.fr/586. Licence: CC BY-NC-ND3.0 IGO Available from:
-
- Harford J.B. Breast-cancer early detection in low-income and middle-income countries: do what you can versus one size fits all. Lancet Oncol. 2011;12:306–312. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
